DelveInsight Blog
Map the latest in Pharmaceutical, Healthcare, Medical Devices and Biotech Space with DelveInsight’s panoramic market analysis while the Pharma Industry continues to rapidly evolve with several approvals,failures, acquisitions, and partnerships teeing up the domain.
ATS 2023 Updats: Dupixent – A Ray of Hope For Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD)
DUPIXENT has shown positive pivotal results for COPD, confirming the key role of IL-4 and IL-13 in type 2 inflammatory diseases. DUPIXENT has the potential to be the first biologic with unprecedented and paradigm-shifting clinical results to treat COPD, having demonstrated a statistically significant reduction in moderate to severe acute exacerbations of COPD, along with improvements in lung function DUPIXENT significantly improved quality of life, and reductions in the severity, with numerical improvements as early as 4 weeks after initiating treatment Chronic obstructive pulmonary disease (COPD) is a life-threatening respiratory disease…
Evaluating the Rising Demand & the Market Potential of the Omega-3 Products
In recent years, the demand for Omega-3 Products has risen exponentially. Omega-3 fatty acids are also referred to as Polyunsaturated fatty acids and work in the body to lower triglycerides, reduce inflammation, and improve heart health, among several other functions. As per DelveInsight’s latest assessment, the global Omega-3 Market is estimated to grow at a CAGR of 7.28% during the forecast period (2022 to 2027). The Omega-3 Market is growing at a significant pace owing to the increase in the prevalence of heart diseases such as stroke, the increasing cases…
FDA Approves Lexicon’s INPEFA (Sotagliflozin); PTC Therapeutics’s Vatiquinone MOVE-FA Registration-Directed Trial; EU Approval to Novartis’s Sickle Cell Disease Drug; EMA Approves Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC; FDA Grants Priority Review to Fruquintinib for mCRC; FDA Orphan Drug Designation to Vega Therapeutics’s VGA039
Lexicon Announces FDA Approval of INPEFA (Sotagliflozin) For Treatment of Heart Failure Lexicon Pharmaceuticals, Inc. announced that the FDA has approved INPEFATM (sotagliflozin), a once-daily oral tablet, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. The broad label includes heart failure patients with any level of left ventricular ejection fraction (LVEF), including preserved and diminished ejection fraction, as well as patients with or without…
-Agonist.png "Toll-like Receptors Agonist")
